What is the recommended dose and dosing frequency of Epclusa (sofosbuvir/velpatasvir) for an adult hepatitis C patient who is treatment‑naïve?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 8, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Recommended Dose and Frequency of Epclusa for Treatment-Naïve Hepatitis C Patients

For treatment-naïve adult patients with hepatitis C, administer Epclusa (sofosbuvir 400 mg/velpatasvir 100 mg) as one tablet taken orally once daily for 12 weeks, regardless of HCV genotype (1-6) or presence of compensated cirrhosis. 1

Dosing Specifications

Standard Adult Regimen:

  • Dose: One fixed-dose combination tablet containing sofosbuvir 400 mg and velpatasvir 100 mg
  • Frequency: Once daily
  • Duration: 12 weeks
  • Food requirement: Can be taken with or without food 1

This recommendation applies uniformly across:

  • All HCV genotypes (1,2,3,4,5, and 6) 2, 3
  • Patients without cirrhosis 1
  • Patients with compensated (Child-Pugh A) cirrhosis 1
  • HCV/HIV-1 coinfected patients 1

Evidence Base

The EASL 2017 guidelines provide Grade A1 recommendations for this regimen across all major genotypes 2. The ASTRAL-1 trial demonstrated 98% SVR12 rates in treatment-naïve patients with genotype 1 infection (including those with cirrhosis), while ASTRAL-2 and ASTRAL-3 showed 99% and 98% SVR12 rates for genotypes 2 and 3, respectively 2. The 2020 EASL update and AASLD/IDSA 2019 guidelines continue to endorse this as a first-line pangenotypic regimen 3, 4.

Important Clinical Considerations

No ribavirin needed: Treatment-naïve patients with compensated cirrhosis or without cirrhosis do NOT require ribavirin addition 2, 1. Ribavirin is only indicated for decompensated cirrhosis (Child-Pugh B or C), where the regimen becomes Epclusa plus weight-based ribavirin for 12 weeks 1.

Renal impairment: No dose adjustment is required for any degree of renal impairment, including patients on dialysis 1.

Mandatory pre-treatment testing: Test all patients for hepatitis B (HBsAg and anti-HBc) before initiating Epclusa due to risk of HBV reactivation 1.

Drug interactions: Review concomitant medications carefully, particularly antiretrovirals in HIV-coinfected patients, as dose adjustments may be needed 1.

Common Pitfalls to Avoid

Do not add ribavirin unnecessarily in treatment-naïve patients with compensated disease—this only increases toxicity without improving efficacy. The high barrier to resistance with this pangenotypic regimen means genotype testing, while helpful for epidemiologic purposes, is not required to initiate treatment 4. Avoid withholding treatment based on ongoing substance use; the SIMPLIFY trial demonstrated 94% SVR12 in people with recent injection drug use 5.

References

Related Questions

When should laboratory monitoring be performed for a patient on Epclusa (sofosbuvir/velpatasvir) 400/100 mg once daily for hepatitis C infection?
In a patient with hepatitis C receiving Epclusa (sofosbuvir + velpatasvir) who has thrombocytopenia, how should the therapy be managed—when to continue, hold, or switch the medication, and what monitoring is recommended?
In a patient with a Fibrosis-4 score of 1.90 and a history of decompensated cirrhosis, should Epclusa (sofosbuvir 400 mg + velpatasvir 400 mg) be started, and what regimen is recommended?
Can Ensativir be taken without Epclusa (sofosbuvir + velpatasvir)?
Is a test of cure (sustained virologic response) required after completing Epclusa (sofosbuvir + velpatasvir) therapy?
When should scrotal Doppler ultrasound be used for suspected testicular torsion, and how do its findings influence management?
Based on the CT findings of mild emphysema, a small Lung‑RADS Category 2 nodule, a remote ground‑glass opacity in the left lower lobe, and pulmonary function tests showing a mild obstructive pattern with partial reversibility, what diagnosis does this evidence support?
What is the appropriate initial management for a 79-year-old male with an 8-day history of acute cervical pain (pain score 7/10) that improves with rest and extension, a brief episode of nausea and vertigo, currently taking flunarizine and etoricoxib for tension-type headache, and awaiting a brain MRI?
What is the recommended dosing, contraindications, and monitoring for hyoscyamine in an adult with gastrointestinal spasm or irritable bowel syndrome?
In patients with gout, which of the following statements are correct: (a) the therapeutic serum uric acid target is the same as in the general population; (b) urate‑lowering therapy should not be discontinued during an acute gout flare; (c) management of hyperuricemia relies solely on pharmacologic treatment; (d) prophylactic colchicine is recommended; (e) elevated serum uric acid in women of child‑bearing age requires further evaluation?
For an 82-year-old male who had coronary artery bypass graft (CABG) surgery on [DATE], has well-controlled hypertension, hyperlipidemia, and type 2 diabetes mellitus, reports intermittent left-sided chest pain for 1.5 months unchanged, has not followed up with cardiology since [DATE] (was advised to follow up in one month), and is scheduled for a tooth extraction, is it advisable to obtain cardiac clearance before the dental procedure?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.